Database studies in asthma pharmacoeconomics: Uses, limitations and quality markers

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 351-358

  Thomas, Mike ^a   Cleland, Jennifer ^a   Price, David ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asthma; Databases; Evidence based medicine; Observational studies

Indexed keywords

ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; STEROID HORMONE;

ASTHMA; CHRONIC DISEASE; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; ECONOMIC EVALUATION; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; RANDOMIZATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; DATABASES, FACTUAL; HUMANS; POPULATION; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037348698     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.351     Document Type: Review

References (31)

1. BARNES PJ, JONSSON B, KLIM JB: The costs of asthma. Eur. Respir. J. (1996) 9:636-642.
2. British Thoracic Society, National Asthma Campaign, RCP: The British guidelines on asthma management: 1995 review and position statement. Thorax (1997) 52:S1-S21.
3. National Asthma Education and Prevention Expert Panel Report 2: guidelines for the diagnosis and management of asthma. 1997. Bethesda, Maryland: NHLBI, NIH Publication No. 97-4051.
4. Asthma management and prevention. Global Initiative for Asthma (GINA). Bethesda, Maryland (1995). NHLBI, NIH Publication 96-3659A.
5. SMITH NM: The 'Needs of People with Asthma' survey and initial presentation of the data. Asthma J. (2000) 5:133-136.
6. MARTINEZ F: Development of wheezing disorders and asthma in preschool children. Pediatrics (2002) 109:129-132.
7. SIMPSON BM, CUSTOVIC A, SIMPSON A et al.: NAC Manchester Asthma and Allergy Study (NACMAAS): risk factors for asthma and allergic disorders in adults. Clin. Exp. Allergy (2001) 31:391-399.
8. Evidence-based medicine: a new approach to teaching the practice of medicine. Evidence-based medicine working group. JAMA (1992) 268(17):2420-2425.
9. MACMAHON S, COLLINS R: Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 357:455-462.
10. BENSON K, HARTZ AJ: A comparison of observational studies and randomised controlled trials. N. Engl. J. Med. (2000) 342:1878-1886.
11. DOLL R: Controlled trials: the 1948 watershed. Br. Med. J. (1998) 317:1217-1220.
12. RADFORD MJ, FOODY JM: How do observational studies expand the evidence base for therapy? JAMA (2001) 286:1228-1229.
13. TEETER JG, BLEECKER ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest (1998) 113:272-277.
14. BARNES NC: Outcome measures in asthma. Thorax (2000) 55:S70-S74.
15. ELPHICK HE, TAN A, ASHBY D, SMYTH RL: Systematic reviews and lifelong diseases. Br. Med. J. (2002) 325:381-384.
16. SHAREK PJ, BERGMAN DA: Beclomethasone for asthma in children: effects on linear growth. In: The Cochrane Library, Issue 4 (2001). Update software.
17. MANN RD, KUBOTA K, PEARCE G, WILTON L: Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J. Clin. Epidemiol. (1996) 49:247-250.
18. ROSENBAUM PR, RUBIN DB: The central role of propensity score in observational studies for causal effects. Biometrika (1983) 70:41-55.
19. PRICE D, THOMAS M, MITCHELL G, NIZIOL C, FEATHERSTONE R: Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. Respir. Med. (2002) 97:12-19.
20. PRICE D, APPLEBY J: Fluticasone propionate: an audit of outcomes and cost effectiveness in primary care. Respir. Med. (1998) 92:351-353.
21. PRICE D, CARGILL K, WOLFE S, DARBY H: Salmeterol xinafoate: an analysis of outcomes and cost effectiveness in primary care. Respir. Med. (1998) 92:1302-1304.
22. O'CONNOR RD, O'DONNELL JC, PINTO LA, WIENER DJ, LEGORRETA AP: Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest (2002) 121:1028-1035.
23. PRICE D, BEN-JOSEPH RH, ZHANG Q: Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir. Med. (2001) 95:83-89.
24. STEMPEL DA, MCLAUGHLIN T, GRIFFIS DL, STANFORD RH: Cost-analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. Respir. Med. (2001) 95:992-998.
25. BROCKLEBANK D, WRIGHT J, CATES C: Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Br. Med. J. (2001) 323:896.
26. BIRNBAUM HG, BERGER WE, GREENBERG PE et al.: Direct and indirect costs of asthma to an employer. J. Allergy Clin. Immunol. (2002) 109:264-270.
27. OZMINKOWSKI RJ, WANG S, MARDER WD, AZZOLINI J, SCHUTT D: Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeconomics (2000) 18:253-264.
28. SUISSA S, ELPHICK HE, BENAYOUN S, BALTZAN M, CAI B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. (2000) 343:332-336.
29. SUISSA S, ERNST P, KEZOUH A: Regular use of inhaled corticosteroids and the long term prevention of hospitalization for asthma. Thorax (2002) 57:880-884.
30. LEGORRETA AP, CHRISTIAN-HERMAN J, O'CONNOR RD, HASAN MM, EVANS R, LEUNG KM: Compliance with national asthma management guidelines and speciality care: a health maintenance organization experience. Arch. Intern. Med. (1998) 158:457-464.
31. LEGORRETA AP, LEUNG KM, BERKBIGLER D, EVANS R, LIU X: Outcomes of a population-based asthma management programme: quality of life, absenteeism and utilization. Ann. Allergy Asthma Immunol. (2000) 85:28-34.